StudyNo,Author,date_published,DOI,Title,Staus,date_first_admit,date_last_admit,date_fup,Country,Province/ region,Study Population,All patients discharged/ dead?,Study design,End point,los_group,Diseases status,Disease status definition,Treatment,Treatment definition,ICU definition (if applicable / available),age_group,plot_cat,covid_severity,grouped_by_severity,other_feature_comorbidity,trt_group,other_group,outcome,N,perc_male,perc_male_specific_for_group,Age range,age_med,age_q25,age_q75,age_mean,age_sd,age_min,age_max,age_specific_for_group,LOS (unspecified),LOS (non-ICU),LOS ICU,LOS high flow nasal cannula,Symptom onset to admission,Symptom onset to discharge or death,Symptom onset to ICU admission,Symptom onset to death,Length of invasive mechanical ventilation,Length of non invasive mechanical ventilation,Length of oxygden support,Treatment to discharge,Treatment to death,LOS_med,LOS_q25,LOS_q75,LOS_mean,LOS_sd,LOS_min,LOS_max,LOS_nonICU_med,LOS_nonICU_q25,LOS_nonICU_q75,LOS_ICU_med,LOS_ICU_q25,LOS_ICU_q75,LOS_ICU_mean,LOS_ICU_sd,onset_admission_mean,onset_admission_sd,onset_admission_median,onset_admission_q25,onset_admission_q75,onset_discharge_death_median,onset_discharge_death_q25,onset_discharge_death_q75,onset_discharge_death_range1,onset_discharge_death_range2,onset_icu_admission_mean,onset_icu_admission_sd,onset_icu_admission_median,onset_icu_admission_q25,onset_icu_admission_q75,invasive_mechanical_ventillation_median,invasive_mechanical_ventillation_q25,invasive_mechanical_ventillation_q75,oxygen_support_median,oxygen_support_q25,oxygen_support_q75,treatment_discharge_median,treatment_discharge_q25,treatment_discharge_q75,treatment_death_median,treatment_death_q25,treatment_death_q75,,Notes
1,Bhatraju et al.,30/03/2020,10.1056/NEJMoa2004500,Covid-19 in Critically Ill Patients in the Seattle Region - Case Series,Published,24/02/2020,09/03/2020,23/03/2020,USA,"Seattle, Washington",Patients with laboratory-confirmed Covid-19 infection who were admitted to nine hospital ICUs in the Seattle region,No,Cohort,Discharge or death,general,,,,,,adult,main,All,N,,,,All,24,63,Y,64±18 [23–97] mean ± SD [range],,,,64,18,23,97,Y,12 (8-18),,9 (4-14) median (IQR),,7±4,,,,10 (7-12),,,,,12,8,18,,,,,,,,9,4,14,,,7,4,,,,,,,,,,,,,,10,7,12,,,,,,,,,,,Not all patients in this study were discharged. Once discharged from ICU several patients were transferred to ward.
,Bhatraju et al.,,,,,,,,US,,,No,,Survivors,general,,,,,,adult,main,All,N,,,,Alive,12,63,N,,,,,64,18,23,97,N,17 (16-23),,14 (4-17),,,,,,,,,,,17,16,23,,,,,,,,14,4,17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2,Cai et al.,02/04/2020,10.1111/all.14309,"COVID-19 in a Designated Infectious Diseases Hospital Outside Hubei Province, China.",Published,11/01/2020,06/02/2020,06/03/2020,China,"Shenzhen, Guangdong",patients with confirmed COVID-19 admitted Third People's Hospital of Shenzhen,No,Cohort,Discharge or death,general,Allpatients,,,,,adult,main,All,Y,,,,All,298,48.66,Y,47.5 (33-61) median (IQR),47.5,33,61,,,,,Y,20.5 (15-26) median (IQR),,,,5 (2-7) median (IQR),,,,,,,,,20.5,15,26,,,,,,,,,,,,,,,5,2,7,,,,,,,,,,,,,,,,,,,,,,,,Patients remained hospitalised at the end of the study. It was unclear whether LOS was reported for only dead/discharged patients or also included still-hospitalised patients.
,Cai et al.,,,,,,,,China,,,No,,Discharge or death,general,Non-severe,based on image assessment,,,,adult,,Non-severe,Y,,,,All,240,44.17,Y,41 (31-56) median IQR,41,31,56,,,,,Y,19 (15-25) median (IQR),,,,4.5 (2.0-7.0) median (IQR),,,,,,,,,19,15,25,,,,,,,,,,,,,,,4.5,2,7,,,,,,,,,,,,,,,,,,,,,,,,
,Cai et al.,,,,,,,,China,,,No,,Discharge or death,general,Severe,based on image assessment,,,,adult,,Severe,Y,,,,All,58,67.24,Y,62.5 (56 - 66) median (IQR),62.5,56,66,,,,,Y,27 (21-34) median (IQR),,,,5 (4.0 - 6.8) median (IQR),,,,,,,,,27,21,34,,,,,,,,,,,,,,,5,4,6.8,,,,,,,,,,,,,,,,,,,,,,,,
3,Cao et al.,18/03/2020,10.1056/NEJMoa2001282,A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19,Published,18/01/2020,03/02/2020,03/02/2020,China,"Wuhan, Hubei",Laboratory-confirmed COVID-19 patients admitted to Jin Yin-Tan Hospital,No,RCT,Discharged or death,general/ICU,,,All,,,adult,main,All,N,,,,All,199,60.3,Y,58.0 (49.0–68.0) median (IQR),58,49,68,,,,,Y,15 (12 to 17) median (IQR),,10 (5 to 14),,,,,,5 (3 to 9) median (IQR),,13 (8 to 16) median (IQR),13 (10 to 16) median (IQR),10 (6 to 15) median (IQR),15,12,17,,,,,,,,10,5,14,,,,,,,,,,,,,,,,,,5,3,9,13,8,16,13,10,16,10,6,15,,Patients still hospitalised at the end of the study. Not clear on the number of deaths.
,Cao et al.,,,,,,,,China,,,No,,Discharge,general/ICU,,,All,,,adult,main,All,N,,,,Alive,155,60.3,N,,58,49,68,,,,,N,,,10 (8 to 17) median (IQR),,,,,,,,,,,,,,,,,,,,,10,8,17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Cao et al.,,,,,,,,China,,,No,,Death,general/ICU,,,All,,,adult,main,All,N,,,,Dead,44,60.3,N,,58,49,68,,,,,N,,,10 (4 to 14) median (IQR),,,,,,,,,,,,,,,,,,,,,10,4,14,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Cao et al.,,,,,,,,China,,,No,,Discharged or death,general/ICU,,,lopinavir-ritonavir,"lopinavir-ritonavir: 400 mg and 100 mg, orally, twice daily plu standard of care:",,adult,,All,N,,lopinavir-ritonavir,lopinavir-ritonavir,All,99,61.6,Y,58.0 (50.0–68.0) median (IQR),58,50,68,,,,,Y,14 (12 to 17) median (IQR),,6 (2 to 11) median (IQR),,,,,,4 (3 to 7) median (IQR),,12 (9 to 16) median (IQR),12 (10 to 16) median (IQR),9 (6 to 13) median (IQR,14,12,17,,,,,,,,6,2,11,,,,,,,,,,,,,,,,,,4,3,7,12,9,16,12,10,16,9,6,13,,
,Cao et al.,,,,,,,,China,,,No,,Discharge,general/ICU,,,lopinavir-ritonavir,,,adult,,All,N,,lopinavir-ritonavir,lopinavir-ritonavir,Alive,80,61.6,N,,58,50,68,,,,,N,,,9 (5 to 44) median (IQR),,,,,,,,,,,,,,,,,,,,,9,5,44,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Cao et al.,,,,,,,,China,,,No,,Death,general/ICU,,,lopinavir-ritonavir,,,adult,,All,N,,lopinavir-ritonavir,lopinavir-ritonavir,Dead,19,61.6,N,,58,50,68,,,,,N,,,6 (2 to 11) median (IQR),,,,,,,,,,,,,,,,,,,,,6,2,11,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Cao et al.,,,,,,,,China,,,No,,Discharged or death,general/ICU,,,Standard treatment,,,adult,,All,N,,Standard treatment,Standard treatment,All,100,59,Y,58.0 (48.0–68.0) median (IQR),58,48,68,,,,,Y,16 (13 to 18) median (IQR),,11 (7 to 17) median (IQR),,,,,,5 (3 to 9) median (IQR),,13 (6 to 16) median (IQR),14 (11 to 16) median (IQR),12 (6 to 15) median (IQR),16,13,18,,,,,,,,11,7,17,,,,,,,,,,,,,,,,,,5,3,9,13,6,16,14,11,16,12,6,15,,
,Cao et al.,,,,,,,,China,,,No,,Discharge,general/ICU,,,Standard treatment,,,adult,,All,N,,Standard treatment,Standard treatment,Alive,75,59,N,,58,48,68,,,,,N,,,11 (9 to 14) median (IQR),,,,,,,,,,,,,,,,,,,,,11,9,14,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Cao et al.,,,,,,,,China,,,No,,Death,general/ICU,,,Standard treatment,,,adult,,All,N,,Standard treatment,Standard treatment,Dead,25,59,N,,58,48,68,,,,,N,,,12 (7 to 17) median (IQR),,,,,,,,,,,,,,,,,,,,,12,7,17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
4,Cao et al.,02/04/2020,10.1093/cid/ciaa243,"Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease 2019 in Wuhan, China.",Published,03/01/2020,01/02/2020,15/02/2020,China,"Wuhan, Hubei",All lab-confirmed patients with COVID-19 admitted to Wuhan University Zhongnan Hospital,Yes,Cohort,Survival or death,general,All,,,,,adult,main,All,N,,,,All,102,52,Y,54(37-67) median (IQR),54,37,67,,,,,Y,11(7-15) median (IQR),,,,6(3-7) median (IQR),,,,,,,,,11,7,15,,,,,,,,,,,,,,,6,3,7,,,,,,,,,,,,,,,,,,,,,,,,
,Cao et al.,,,,,,,,China,,,Yes,,,general,Survivors,,,,,adult,main,All,N,,,,Alive,17,76.5,Y,72(63-81) median (IQR),72,63,81,,,,,Y,9(6-17) median (IQR),,,,6(3-8) median (IQR),,,,,,,,,9,6,17,,,,,,,,,,,,,,,6,3,8,,,,,,,,,,,,,,,,,,,,,,,,
,Cao et al.,,,,,,,,China,,,Yes,,,general,Non-survivors,,,,,adult,main,All,N,,,,Dead,85,47.1,Y,53(47-66) median (IQR),53,47,66,,,,,Y,11(7-14) median (IQR),,,,6(3-7) median (IQR),,,,,,,,,11,7,14,,,,,,,,,,,,,,,6,3,7,,,,,,,,,,,,,,,,,,,,,,,,
5,Chen et al,11/03/2020,11/03/2020,"Clinical progression of patients with COVID-19 in Shanghai, China.",Published,20/01/2020,06/02/2020,25/02/2020,China,Shanghai,"Recruited patients admitted to Shanghai Public Health Clinical Center (SPHCC), diagnosed with COVID-19 according to Chinese national guideline for COVID-19 diagnosis and treatment, as well as the World Health Organization interim guidance.",No,Cohort,Discharge,general,,,,,,adult,main,All,N,,,,Alive,215,50.6,Y,51.0 (36.0–64.0) median (IQR),51,36,64,,,,,Y,16(12–20) median (IQR)?,,,,"4(2–7) median (IQR)*
 *in patients with symptoms",,8.5 ± 4.0 mean sd?,,,,,,,16,12,20,,,,,,,,,,,,,,,,,,,,,,,8.5,4,,,,,,,,,,,,,,,,,Not all patients in this study were discharged.
6,Chen et al.,26/03/2020,10.1136/bmj.m1091,Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study,Published,13/01/2020,12/02/2020,28/02/2020,China,"Wuhan, Hubei",All COVID-19 confirmed patients admitted to Tongji Hospital,No,Cohort,Discharge or death,general,"moderately, severely or critically ill",according to the guidance for corona virus disease 2019 (6th edition) released by the National Health Commission of China.,,,NA,adult,main,All,N,,,,All,274,62.4,Y,62.0 (44.0-70.0) median (IQR),62,44,70,,,,,Y,13.0 (6.0 - 17.0) median (IQR),,,,10.0 (7.0-12.0) median (IQR),22.0 (16.8 - 27.3) meadian (IQR),,,,,,,,13,6,17,,,,,,,,,,,,,,,10,7,12,22,16.8,27.3,,,,,,,,,,,,,,,,,,,,,Patients still hospitalised at the end of the study.
,Chen et al.,,,,,,,,China,,,No,,Discharge,general,,,,,NA,adult,main,All,N,,,,Alive,161,54.7,Y,51 (37 - 66) median (IQR),51,37,66,,,,,Y,16.0 (14.0 - 19.0) median (IQR),,,,9.0 (6.0-12.0) median (IQR),26.0 (21.8 - 29.0) median (IQR),,,,,,,,16,14,19,,,,,,,,,,,,,,,9,6,12,26,21.8,29,,,,,,,,,,,,,,,,,,,,,
,Chen et al.,,,,,,,,China,,,No,,Death,general,,,,,NA,adult,main,All,N,,,,Dead,113,73.4,Y,68 (62 - 77) median (IQR),68,62,77,,,,,Y,5.0 (3.0 - 9.3) median (IQR),,,,10.0 (7.0-13.0) median (IQR),16.0 (12.0 - 20.0) median (IQR),,16.0 (12.0 - 20.0) median (IQR),,,,,,5,3,9.3,,,,,,,,,,,,,,,10,7,13,16,12,20,,,,,,,,,,,,,,,,,,,,,
7,Chen et al.,06/03/2020,10.1101/2020.03.03.20030353,"Epidemiological and clinical features of 291 cases with coronavirus disease 2019 in areas adjacent to Hubei, China: a double-center observational study",Published,23/01/2020,14/02/2020,20/02/2020,China,Hunan,All patients with confirmed COVID-19 admitted to the first Hospital of Changsha and Loudi Central Hospital,No,Cohort,Discharge,general,Discharged,,,,,adult,main,All,N,,,,Alive,159,49.8,N,47 (34-59) [1-84] median (IQR) [range],46,34,59,,,1,84,N,12 (10-15) median (IQR) range 5 - 25,,,,,,,,,,,,,12,10,15,,,5,25,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Two estimates of LOS were provided in this study, one estimate for discharged patients only, and one estimate for all patients (including still-hospitalised). The estimate which included still-hospitalised patients was excluded."
,Chen et al.,,,,,,,,China,,,No,,,general,Mild,,,,,adult,,Mild,N,,,,Alive,9,55.2,N,50 (34.5-53) [2-76],50,34.5,53,,,2,76,N,16 (12.5-21.5) (n = 9),,,,6 (3-11),,,,,,,,,16,12.5,21.5,,,,,,,,,,,,,,,6,3,11,,,,,,,,,,,,,,,,,,,,,,,,
,Chen et al.,,,,,,,,China,,,No,,,general,Moderate,,,,,adult,,Moderate,N,,,,Alive,121,48.1,N,41 (32-53) [2-84],41,32,53,,,2,84,N,12 (9-14) (n = 121),,,,5 (3-8),,,,,,,,,12,9,14,,,,,,,,,,,,,,,5,3,8,,,,,,,,,,,,,,,,,,,,,,,,
,Chen et al.,,,,,,,,China,,,No,,,general,Severe/critical,,,,,adult,,Severe,N,,,,Alive,29,54,N,60.5 (46-70) [1-82],60.5,46,70,,,1,82,N,14 (13-17) (n = 29),,,,6 (4-9),,,,,,,,,14,13,17,,,,,,,,,,,,,,,6,4,9,,,,,,,,,,,,,,,,,,,,,,,,
8,Cheng et al,20/03/2020,10.1101/2020.02.18.20023242,Kidney disease is associated with in-hospital death of patients with COVID-19,Published,28/01/2020,11/02/2020,17/02/2020,China,"Wuhan, Hubei",All COVID-19 patients admitted to Tongji hospital,No,Cohort,Death,general,,,,,NA,adult,main,All,N,,,,Dead,113,52.4,N,63 (50–71),63,50,71,,,,,N,"6 days (interquartile range, 3–12 days)",,,,,,,,,,,,,6,3,12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
9,Ding et al.,26/03/2020,10.1002/jmv.25781,"The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China.",Published,,,,China,"Wuhan, Hubei",Patients infected with both influenza and COVID-19 admitted to Tongji Hospital,Yes,Cohort,Discharge,general,,,,,,adult,main,All,N,,,,Alive,5,40,Y,39-66,49,,,50.2,,39,66,Y,"18.4 ± 7.02 (mean, sd)",,,,,,,,,,,,,,,,18.4,7.02,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10,Du et al.,03/04/2020,10.1164/rccm.202003-0543OC,Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study.,Published,09/01/2020,15/02/2020,15/02/2020,China,Hubei,Severe patients with confirmed COVID-19 admitted Hannan Hospital and Wuhan Union Hospital,Yes,retrospective observational,Death,general,Severe,unclear but seems to mean fatal.,,,,adult,main,Severe,N,,,,Dead,85,72.9,Y,65.8±14.2,,,,65.8,14.2,,,Y,"6.35 ± 4.51 
 (range 1 to 21) mean (sd)",,,,10.1 ± 6.2 mean (sd),,,,,,,,,,,,6.35,4.51,1,21,,,,,,,,,10.1,6.2,,,,,,,,,,,,,,,,,,,,,,,,,,,LOS was only reported for deaths.
11,Fan et al.,05/03/2020,10.1101/2020.02.26.20026971,Clinical Features of COVID-19-Related Liver Damage,Published,20/01/2020,31/01/2020,19/02/2020,China,Shanghai,All confirmed COVID-19 cases in Shanghai Public Health Clinical Center,No,Retrospective cohort,Discharge,general,Normal and abnormal liver function,,,,NA,adult,main,All,N,,,,Alive,93,49.3,N,"50.5 years (interquartilerange,36-64)",50.5,36,64,,,15,88,N,12 days (6-21 days),,,,,,,,,,,,,,,,12,,6,21,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Fan et al.,,,,,,,,China,,,No,Cohort,Discharge,general,Normal liver function,,,,,adult,,All,N,Normal liver function,,Normal liver function,Alive,27,38.4,N,,50.5,36,64,,,,,N,12.67±5.31,,,,,,,,,,,,,,,,12.67,5.31,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Fan et al.,,,,,,,,China,,,No,,Discharge,general,Abnormal liver function,"(abnormal liver damage was defined as any parameter more than the upper 
 limit of normal value (ULN) of ALT (40 U/L), AST（35 U/L), ALP(100 U/L), 
 GGT(45 U/L), TB(20.5 umol/L), LDH(245 U/L))",,,,adult,,All,N,Abnormal liver function,,Abnormal liver function,Alive,66,62.7,N,,50.5,36,64,,,,,N,15.14±4.58,,,,,,,,,,,,,,,,15.14,4.58,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,All confirmed COVID-19 cases in Shanghai Public Health Clinical Center
12,Graselli et al,06/04/2020,10.1001/jama.2020.5394,"Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy",Published,20/02/2020,18/03/2020,25/03/2020,Italy,Lombardy,"All patients with laboratory-confirmed COVID-19, referred to Ospedale Maggiore Policlinico, and subsequently admitted to one of the ICUs among 72 hospitals in the network",No,Cohort,ICU discharge/death,ICU,,,,,,adult,main,Severe,N,,,,All,1591,82,Y,63 (56-70) median (IQR),63,56,70,,,,,Y,,,9 (6-13) median (IQR),,,,,,,,,,,,,,,,,,,,,9,6,13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Patients still hospitalised at the end of the study.
,Graselli et al,,,,,,,,Italy,,Patients discharged from ICU,No,,ICU discharge,ICU,,,,,,adult,main,Severe,N,,,,Alive,256,82,N,,63,56,70,,,,,N,,,8 (5-12),,,,,,,,,,,,,,,,,,,,,8,5,12,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Graselli et al,,,,,,,,Italy,,Patients who died in ICU,No,,Death,ICU,,,,,,adult,main,Severe,N,,,,Dead,405,82,N,,63,56,70,,,,,N,,,7 (5-11),,,,,,,,,,,,,,,,,,,,,7,5,11,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
13,Guan et al.,28/02/2020,10.1056/NEJMoa2002032,Clinical Characteristics of Coronavirus Disease 2019 in China.,Published,11/12/2020,29/01/2020,31/01/2020,China,National,Hospitalized lab confirmed cases of COVID-19 from 552 hospitals in 30 provinces in China.,No,Cohort,Discharge and death,general,,,,,,adult,main,All,Y,,,,All,1099,58.1,Y,47.0 (35.0 - 58.0) median (IQR),47,35,58,,,,,Y,12.0(10.0 - 14.0) median IQR,,,,,,,,,,,,,12,10,14,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1029 /1099 patients were still hospitalised.
,Guan et al.,,,,,,,,China,,,No,,Discharge and death,general,Non-severe,American Thoracic Society guidelines for community-acquired pneumonia,,,,adult,,Non-severe,Y,,,,All,926,58.2,Y,45 (34.0 - 57.0) median (IQR),45,34,57,,,,,Y,11.0 (10.0 - 13.0) median IQR,,,,,,,,,,,,,11,10,13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Guan et al.,,,,,,,,China,,,No,,Discharge and death,general,Severe,,,,,adult,,Severe,Y,,,,All,173,57.8,Y,52.0 (40.0 - 65.0),52,40,65,,,,,Y,13.0 (11.5 - 17.0) median IQR,,,,,,,,,,,,,13,11.5,17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
14,ICNARC,16/04/2020,https://www.icnarc.org/DataServices/Attachments/Download/c31dd38d-d77b-ea11-9124-00505601089b,ICNARC report on COVID-19 in critical care,Other,,16/04/2020,,UK,National,Patients critically ill with confirmed COVID-19 reported to ICNARC up to 16 April 2020 from critical care units participating in the Case Mix Programme. This is a national audit that is being continually updated.,No,Cross-sectional,Discharge,ICU,Severe (HDU/ICU),,,,,adult,main,Severe,N,,,,Alive,1437,46.7,Y,"60 (52, 68) median (IQR) / 59.5 (12.6) mean (SD)",60,52,68,59.5,12.6,,,N,,,"5 (2, 9) median (IQR)",,,,,,,,,,,,,,,,,,,,,5,2,9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Patients still hospitalised at the end of the study.
,ICNARC,,,,,,,,UK,,,No,,Death,ICU,Severe (HDU/ICU),,,,,adult,main,Severe,N,,,,Dead,1499,53.3,Y,"60 (52, 68) median (IQR) / 59.5 (12.6) mean (SD)",60,52,68,59.5,12.6,,,N,,,"6 (4, 10) median (IQR)",,,,,,,,,,,,,,,,,,,,,6,4,10,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
15,ISARIC,08/04/2020,https://media.tghn.org/medialibrary/2020/04/ISARIC_Data_Platform_COVID-19_Report_8APR20.pdf,International Severe Acute Respiratory and Emerging InfectionsConsortium (ISARIC),Other,,25/03/2020,,Worldwide (25 countries),,Hospitalised patients with confirmed or suspected COVID-19 submitted electronically by participating sites to the ISARIC database.,No,Cohort,All (including still hospitalised),,,,,,,adult,,All,N,,,,All,3316,53,Y,71 (median) range (0-104),71,,,,,0,104,Y,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Patients still hospitalised at the end of the study. Age and sex is only available for all patients. Majority of data is from the UK (82%). LOS estimates were only provided for discharges and deaths.
,ISARIC,,,,,,,,Worldwide (25 countries),,,No,,Discharge or death,general,,,,,,adult,main,All,N,,,,All,1567,53,N,,71,,,,,0,104,N,7.2 (SD 6.6),,,,,,,,,,,,,,,,7.2,6.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ISARIC,,,,,,,,Worldwide (25 countries),,,No,,Discharge or death,ICU,,,,,,adult,main,All,N,,,,All,244,53,N,,71,,,,,0,104,N,,,6.3 days (SD: 5.2 days),,,,,,,,,,,,,,,,,,,,,,,,6.3,5.2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16,Liu et al.,13/03/2020,10.1101/2020.03.09.20033118,"Epidemiological, Clinical Characteristics and Outcome of Medical Staff Infected with COVID-19 in Wuhan, China: A Retrospective Case Series Analysis",Pre-print,16/01/2020,15/02/2020,,China,"Wuhan, Hubei",Confirmed cases of COVID-19 medical staff admitted to Union Hospital,No,Cohort,Discharge,general,,,,,,adult,main,All,N,,,,Alive,64,36,Y,35 (29-43) median (IQR),35,29,43,,,,,Y,12.5 (9-19.8) median (IQR),,,,8.5 (4.3-15) median (IQR),,,,,,,,,12.5,9,19.8,,,,,,,,,,,,,,,8.5,4.3,15,,,,,,,,,,,,,,,,,,,,,,,,Patients still hospitalised at the end of the study.
,Liu et al.,,,,,,,,China,,onset-admission <= 10days,No,,,general,,,,,,adult,,All,N,onset-admission <= 10 days,,onset-admission <= 10 days,Alive,37,46,Y,37 (32-44),37,32,44,,,,,Y,18 (13-20.5),,,,5 (3-7),,,,,,,,,18,13,20.5,,,,,,,,,,,,,,,5,3,7,,,,,,,,,,,,,,,,,,,,,,,,
,Liu et al.,,,,,,,,China,,onset-admission > 10days,No,,,general,,,,,,adult,,All,N,onset-admission > 10 days,,onset-admission > 10 days,Alive,25,24,Y,30 (27-36),30,27,36,,,,,Y,9 (6-11),,,,18 (14-24),,,,,,,,,9,6,11,,,,,,,,,,,,,,,18,14,24,,,,,,,,,,,,,,,,,,,,,,,,
17,Liu et al.,12/03/2020,10.1016/j.ijid.2020.03.013,Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression,Published,22/01/2020,11/02/2020,11/02/2020,China,"Hangzhou, Zhejiang","Patients with confirmed COVID-19, admitted to Xixi hospital",No,Cohort,"Discharged (3 transferred, 7 discharged)",general,,,lopinavir,,,adult,main,All,N,,,,Alive,10,40,Y,42 ( 34–50) median (IQR),42,34,50,,,,,Y,13 (4–17) median (IQR),,,,,,,,,,,,,13,4,17,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Patients still hospitalised at the end of the study (3 transferred to ICU)
18,Liu et al.,23/02/2020,10.1101/2020.02.20.20025536,"Clinical characteristics of 51 patients discharged from hospital with COVID-19 in Chongqing, China",Pre-print,20/01/2020,03/02/2020,,China,Chongqing,"hospitalized patients with confirmed COVID-19 at Chongqing University Three Gorges Hospital in Chongqing, China, from January 20 to February 3, 2020",Yes,Cohort,Discharge or death,general,All,,,,,adult,main,All,Y,,,,All,51,62.7,Y,"45 years (interquartile range, 34-51; range, 16-68 years)",45,34,51,,,16,68,Y,12 (9-13) median (IQR),,,,,,,,,,,,,12,9,13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"One death, all others discharged"
,Liu et al.,,,,,,,,China,,,Yes,,,general,Non-Severe,,,,,adult,,Non-severe,Y,,,,All,44,63.7,Y,44 (33-49),44,33,49,,,,,Y,12 (9-13),,,,,,,,,,,,,12,9,13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Liu et al.,,,,,,,,China,,,Yes,,,general,Severe,World Health Organization interim guidance/The National Health and Health Commission of the people's Republic of China,,,,adult,,Severe,Y,,,,All,7,57.1,Y,52 (44-60),52,44,60,,,,,Y,15 (9-16),,,,,,,,,,,,,15,9,16,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
19,Mo et al.,16/03/2020,10.1093/cid/ciaa270,"Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China.",Published,01/01/2020,05/02/2020,,China,"Wuhan, Hubei",All patients confirmed COVID-19 patients admitted to Zhongnan Hospital,No,Cohort,Death,general,,,,,,adult,main,All,N,,,,Dead,22,,,,,,,,,,,,10.5 (8~16) median (IQR),,,,,,,,,,,,,10.5,8,16,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"LOS is reported for both deaths and discharges, however, sample size was only reported for deaths, so the LOS for discharges was excluded. Age and sex of the population were not provided."
,Mo et al.,,,,,,,,China,,,No,,Recovered,general,,,,,,adult,main,All,N,,,,Alive,,,,,,,,,,,,,10 (7~15) median (IQR),,,,,,,,,,,,,10,7,15,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20,Pan et al.,13/02/2020,10.1148/radiol.2020200370,Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia.,Published,12/01/2020,06/02/2020,,China,"Wuhan, Hubei","Patients with RT-PCR confirmed COVID-19 infection presenting at Union Hospital, Tongji Medical College. Patients with severe respiratory distress and/ or oxygen requirement at any time during the disease course were excluded.",Yes,Cohort,Discharge,general,,,,,,adult,main,Non-severe,N,,,,Alive,21,29,Y,40 ± 9 [25 -63] mean±SD [range],,,,40,9,25,63,Y,17 ± 4 [11 -26] mean±SD [range],,,,,,,,,,,,,,,,17,4,11,26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Severe cases were excluded from this study.
21,Qi et al.,03/03/2020,10.1101/2020.03.01.20029397,"Epidemiological and clinical features of 2019-nCoV acute respiratory disease cases in Chongqing municipality, China: a retrospective, descriptive, multiple-center study",Pre-print,19/01/2020,16/02/2020,16/02/2020,China,Chongqing,"Laboratory-confirmed COVID-19 patients admitted to 3 designated-hospitals (Qianjiang central hospital of Chongqing, Chongqing three gorges central hospital and Chongqing public health medical center) in Chongqing provincial municipality",No,Cohort,Death or discharge (not clear),general,All,,,,,adult,main,All,Y,,,,All,164,55.8,Y,48 (35-65) [20-80] median (IQR) [range],48,35,65,,,20,80,Y,15 (11.5-16) [9-25] (median(IQR) [range]),,,,7 (3-10) median (IQR),,,,,,,,,15,11.5,16,,,9,25,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Patients still hospitalised at the end of the study. Not clear whether they have included patients still admitted to hospital or limited to only those that have been dead of discharged within their LOS estimate
,Qi et al.,,,,,,,,China,,,No,,,general,Severe,American Thoracic Society guideline,,,,adult,,Severe,Y,,,,All,44,78,Y,71.5 (65.8-77) [39-80],71.5,65.8,77,,,39,80,Y,20 (17.5-23.25) [14-25],,,,9 (6-12.75),,,,,,,,,20,17.5,23.25,,,14,25,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Qi et al.,,,,,,,,China,,,No,,,general,Non-severe,,,,,adult,,Non-severe,Y,,,,All,120,50.7,Y,43 (32.5-57) [20-79],43,32.5,57,,,20,79,Y,14 (11-16) [9-16],,,,6 (3-9),,,,,,,,,14,11,16,,,9,16,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
22,Qui et al,25/03/2020,10.1016/S1473-3099(20)30198-5,"Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study",Published,17/01/2020,,01/03/2020,China,"Wenzhou, Zhejiang","Paediatric patients (aged 0–16 years) with confirmed COVID-19 from electronic medical records in three hospitals in Zhejiang, China (Ningbo Women and Children's Hospital, The Third Affiliated Hospital of Wenzhou Medical University, and Wenzhou Central Hospital of Wenzhou)",Yes,Cohort,Discharge,general,Mild and moderate cases,,,,NA,pediatric,main,Non-severe,Y,,,,Alive,36,63.9,Y,"Age 8·3 (3·5, 1–16) mean (SD, range)",,,,8.3,3.5,1,16,Y,"14 (3, 10-20) mean (SD, range)",,,,,,,,,,,,,,,,14,3,10,20,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Qui et al,,,,,,,,China,,,Yes,,Discharge,general,Mild cases,"Upper respiratory symptoms (eg, pharyngeal congestion, sore throat, and fever) for a short duration or asymptomatic infection; Positive RT-PCR test for SARS-CoV-2; No abnormal radiographic and septic presentation",,,,pediatric,,Mild,Y,,,,Alive,17,59,Y,"Age 7.5 (3·2, 1–16) mean (SD, range)",,,,7.5,3.2,1,16,Y,"12 (3, 10–16) mean (SD, range)",,,,,,,,,,,,,,,,12,3,10,16,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Qui et al,,,,,,,,China,,,Yes,,Discharge,general,Moderate cases,"Mild pneumonia; Symptoms such as fever, cough, fatigue, headache, and myalgia; No complications and manifestations related to severe conditions",,,,pediatric,,Moderate,Y,,,,Alive,19,68,Y,"Age 9.0 (3.6, 1–16) mean (SD, range)",,,,9,3.6,1,16,Y,"15 (4, 12–20) mean (SD, range)",,,,,,,,,,,,,,,,15,4,12,20,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
23,Shen et al.,27/03/2020,10.1001/jama.2020.4783,Treatment of 5 Critically Ill Patients WithCOVID-19 With Convalescent Plasma,Published,20/01/2020,25/03/2020,25/03/2020,China,"Shenzhen, Guangdong","Laboratory-confirmed COVID-19 and acute respiratory distress syndrome (ARDS) who were admitted to Shenzhen Third People's Hospital who met the
 following criteria: severe pneumonia with rapid progression and continuously high viral load
 despite antiviral treatment; PAO2/FIO2 <300; and mechanical ventilation.",No,Cohort,Discharge (3) & still hospitalised (2),general,Severe (ARDS),,,,,adult,,Severe,N,,,,Alive,5,60,Y,[36-73],55,,,,,36,73,Y,,,,,2 [2-4] median [range],,,,,,,,,,,,,,,,,,,,,,,,,,2,2,4,,,,,,,,,,,,,,,,,,,,,,,,Patients still hospitalised at the end of the study.
,Shen et al.,,,,,,,,China,,,No,,Discharge,general,,,,,,adult,main,Severe,N,,,,Alive,3,60,N,,55,,,,,36,73,N,"51, 53, 55 days",,,,,,,,,,,,,53,,,,,51,55,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
24,Shi et al.,10/03/2020,10.21037/atm.2020.03.22,"A quickly, effectively screening process of novel corona virus disease 2019 (COVID-19) in children in Shanghai, China.",Published,19/01/2020,08/02/2020,15/02/2020,China,Shanghai,"Children admitted to outpatient and emergency department Children’s Hospital of Fudan University, Shanghai",No,Cohort,Study end (4 discharged - remaining 6 still hospitalised at study end),general,,,,,NA,pediatric,main,All,N,,,,Alive,10,50,Y,"7 months to 11 years, the average age is 6.0±4.2",,,,6,4.2,0.58,11,Y,10 days (average),,,,,,,,,,,,,,,,10,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Only 4 patients had been discharged when LOS was calculated.
25,Shi et al.,08/04/2020,10.1101/2020.03.28.20046144,The potential of low molecular weight heparin to mitigate cytokine storm in severe covid-19 patients: a retrospective clinical study,Pre-print,02/02/2020,16/03/2020,,China,"Wuhan, Hubei","Patients with COVID-19 (severe clinical classification) treated at the Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",Yes,Cohort,Discharge,general,,,Heparin,low 50 molecular weight heparin (LMWH),,adult,main,Severe,N,,Heparin,Heparin,Alive,21,62,Y,69 [42-91] median [range],69,,,,,42,91,Y,29 (17-42) (IQR),,,,,,,,,,,,,29,17,42,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,No critical cases
,Shi et al.,,,,,,,,China,,,Yes,,,general,,,Control,,,adult,main,Severe,N,,Control,Control,Alive,21,67,Y,69 [40-84],69,,,,,40,84,Y,27 (24-31),,,,,,,,,,,,,27,24,31,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26,Shi et al.,25/03/2020,10.1001/jamacardio.2020.0950,"Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China.",Published,20/01/2020,10/02/2020,15/02/2020,China,"Wuhan, Hubei",Patients with laboratory-confirmed COVID-19 admitted to Renmin Hospital,No,Cohort,Death,general,Cardiac injury,"blood levels of cardiac biomarkers (hs-TNI) above the 99th-percentile upper reference limit, regardless of new abnormalities in electrocardiography and echocardiograph",,,,adult,main,All,N,Cardiac injury,,Cardiac injury,Dead,42,53.7,Y,74 (34-95),74,,,,,34,95,Y,6.3 (1 - 16) mean (range),,,,,,,15.6 (1 - 37) mean(range),,,,,,,,,6.3,,1,16,,,,,,,,,,,,,,15.6,,,1,37,,,,,,,,,,,,,,,,,,,Only report LOS for those who have died: 77% remained in hospital
,Shi et al.,,,,,,,,China,,,No,,,general,No cardiac injury,,,,,adult,main,All,N,No cardiac injury,,No cardiac injury,Dead,15,48.2,Y,60 (21-90),60,,,,,21,90,Y,7.8 (1 - 23) mean (range),,,,,,,16.9 (3 -37) mean(range),,,,,,,,,7.8,,1,23,,,,,,,,,,,,,,16.9,,,3,37,,,,,,,,,,,,,,,,,,,
27,Shi et al.,24/02/2020,10.1016/S1473-3099(20)30086-4,"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study.",Published,20/12/2020,23/01/2020,08/02/2020,China,"Wuhan, Hubei",Patients with confirmed COVID-19 admitted to Wuhan Jinyintan hospital or Union Hospital of Tongji Medical College,No,Cohort,Discharge,general,type 1,"initial progression to peak level, followed by radiographic improvement",,,,adult,main,All,N,type 1,,type 1,Alive,24,,,,,,,,,,,,25 (20–27) median (IQR),,,,,,,,,,,,,25,20,27,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Patients still hospitalised at the end of the study.
,Shi et al.,,,,,,,,China,,,No,,,general,type 3,radiographic improvement,,,,adult,main,All,N,type 3,,type 3,Alive,5,,,,,,,,,,,,19 (11-25) median (IQR),,,,,,,,,,,,,19,11,25,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
28,Spiteri et al.,05/03/2020,10.2807/1560-7917.ES.2020.25.9.2000178,"First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020.",Published,24/01/2020,21/02/2020,21/02/2020,EU/EEA,EU/EEA,European surveillance data of confirmed COVID-19 patients,No,Cross-sectional,Discharge,general,,,,,,adult,main,All,N,,,,Alive,16,,,,,,,,,,,,13 (8–23) median (range),,,,,,,,,,,,,13,,,,,8,23,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Patients still hospitalised at the end of the study.
,Spiteri et al.,,,,,,,,EU/EEA,,,No,,Death,general/ICU,,,,,,adult,main,All,N,,,,Dead,1,,,,,,,,,,,,21,,19,,,,,,,,,,,21,,,,,,,,,,19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
29,Tang et al.,26/03/2020,10.1016/j.chest.2020.03.032,Comparison of Hospitalized Patients with Acute Respiratory Distress Syndrome Caused by COVID-19 and H1N1,Published,24/12/2019,07/02/2020,,China,"Wuhan, Hubei",Patients with COVID-19-induced ARDS admitted to the Department of Pulmonary and Critical Care at Wuhan Pulmonary Hospital in Hubei Province of China,No,Case-control,Discharge or death,general,,,,,,adult,main,All,N,,,,All,73,61.6,Y,67 (57-72) median (IQR),67,57,72,,,,,Y,13 (10-18) median (IQR),,,,,,,,,,,,,13,10,18,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Not clear whether LOS included patients remaining in hospital, or if they were excluded"
30,Tian et al.,23/03/2020,10.1101/2020.03.21.20038778,"Clinical characteristics and reasons of different duration from onset to release from quarantine for patients with COVID-19 Outside Hubei province, China.",Pre-print,Not provided,Not provided,Not provided,China,"Liaocheng, Shandong",Not stated,Yes,Cohort,Unknown,general,"mild (13.5%), moderate (81.1%), severe (2.7%), and critical (2.7%)",,,,,adult,main,All,N,,,,All,37,45.9,Y,44.3±1.67,,,,44.3,1.67,,,Y,"16.1 ±6.2 [7,32]",,,,4.1±3.7,,,,,,,,,,,,16.1,6.2,7,32,,,,,,,,,4.1,3.7,,,,,,,,,,,,,,,,,,,,,,,,,,,"Not clear what the study population is; location and hospital have been assumed, and study dates have not been provided. Patients still hospitalised at the end of the study."
31,Wang et al.,20/03/2020,10.1016/j.jinf.2020.03.019,Coronavirus Disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up,Published,01/01/2020,06/02/2020,05/03/2020,China,"Wuhan, Hubei","All confirmed cases of COVID-19 over 60 years old admitted to Renmin Hospital of Wuhan University in Wuhan, China.",No,Cohort,"Discharge, hospitalised, or death",general,,,,,,elderly,main,All,N,,,,All,339,49,Y,69 (65-76) median (IQR),69,65,76,,,,,Y,28 (15-28) median (IQR),,,,10 (7-14) median (IQR),,,,,,,,,28,15,28,,,,,,,,,,,,,,,10,7,14,,,,,,,,,,,,,,,,,,,,,,,,"LOS was provided for survivors, however not all survivors had been discharged (91/274), and so this estimate includes still-hospitalised patients."
,Wang et al.,,,,,,,,China,,,No,,Discharge or hospitalised,general,,,,,,elderly,main,All,N,,,,Alive,274,46.4,Y,68 (64-74),68,64,74,,,,,Y,28 (26-29),,,,10 (7-13),,,,,,,,,28,26,29,,,,,,,,,,,,,,,10,7,13,,,,,,,,,,,,,,,,,,,,,,,,
,Wang et al.,,,,,,,,China,,,No,,Death,general,,,,,,elderly,main,All,N,,,,Dead,65,60,Y,76 (70-83),76,70,83,,,,,Y,5 (3-8),,,,10 (7-14),,,,,,,,,5,3,8,,,,,,,,,,,,,,,10,7,14,,,,,,,,,,,,,,,,,,,,,,,,
32,Xia et al.,26/02/2020,10.1002/ppul.24718,Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults.,Published,23/01/2020,08/02/2020,18/02/2020,China,"Wuhan, Hubei",Pediatric inpatients with COVID-19 infection confirmed by pharyngeal swab in Wuhan Children's hospital,No,Cohort,Discharge,general,,,,,,pediatric,main,All,N,,,,Alive,18,65,Y,2y [1 day - 14y] median [range],2,,,,,0.00273973,14,Y,12.9 [8 -20] average [range],,,,,,,,,,,,,,,,12.9,,8,20,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Statistic used for LOS not completely clear. 2 neonates remain under observation but had negative CT findings.
33,Wu et al.,2020-02-30,10.1101/2020.02.26.20028589,Heart injury signs are associated with higher and earlier mortality in coronavirus disease 2019 (COVID-19),Pre-print,26/12/2019,28/01/2020,12/02/2020,China,"Wuhan, Hubei",COVID-19 patients admitted to Wuhan Jinyintan Hospital,Yes,Cohort,Discharge,general,,,,,,adult,main,All,N,,,,Alive,145,63.3,N,,,,,51.9,14.26,,,N,12 (9-14),,,,,,,,,,,,,12,9,14,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Wu et al.,,,,,,,,China,,,Yes,,Death,general,,,,,,adult,main,All,N,,,,Dead,43,63.3,N,,,,,51.9,14.26,,,N,7 (4-11),,,,,,,,,,,,,7,4,11,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
34,Wu et al.,29/02/2020,10.1093/cid/ciaa199,Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study.,Published,22/01/2020,14/02/2020,14/02/2020,China,Jiangsu,"All admitted patients for COVID-19 to First People’s Hospital of Yancheng City, the Second People’s Hospital of Yancheng City, and the Fifth People’s Hospital of Wuxi.",No,Cohort,Discharge,general,,,,,,adult,main,All,N,,,,Alive,21,48.75,Y,46.10 ± 15.42,,,,46.1,15.42,,,Y,mean: 8,,,,,,,,,,,,,,,,8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,80 patients but LOS only reported for those discharged.
35,Wu et al.,13/03/2020,10.1001/jamainternmed.2020.0994,"Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China.",Published,25/12/2019,26/01/2020,13/02/2020,China,"Wuhan, Hubei",Confirmed COVID-19 pneumonia admitted to Wuhan Jinyintan Hospital,No,Cohort,Discharge,general,,,,,,adult,main,All,N,,,,Alive,144,63.7,Y,51 (43-60) median (IQR),51,43,60,,,,,Y,13 (10-16) median (IQR),,,,,,,,,,,,,13,10,16,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Unclear whether LOS included those who died. State that some of their cases have previously been described in other studies. Age and sex are regarding total population (including those remaining in hospital)
36,Xie et al.,02/04/2020,10.1111/liv.14449,Clinical characteristics of Non‐ICU hospitalized patients with coronavirus disease 2019 and liver injury：A Retrospective study,Published,02/02/2020,23/02/2020,,China,"Wuhan, Hubei",All laboratory-confirmed COVID-19 discharged patients from the non-ICU Ward at Wuhan Jinyintan Hospital,Yes,Cohort,,,all,,,,,adult,main,Non-severe,N,,,,Alive,79,55.7,Y,60 (48-66) median (IQR),60,48,66,,,,,Y,,,,,12 median,,,,,,,,,,,,,,,,,,,,,,,,,,12,,,,,,,,,,,,,,,,,,,,,,,,,,"Non-ICU LOS reported. Study dates are based on discharge dates, not admission dates."
,Xie et al.,,,,,,,,China,,,Yes,,,general,with liver injury,,,,,adult,,Non-severe,N,with liver injury,,with liver injury,Alive,50,44.7,Y,56(45-65),56,45,65,,,,,Y,,11.4 (8.5-14),,,,,,,,,,,,,,,,,,,11.4,8.5,14,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Xie et al.,,,,,,,,China,,,Yes,,,general,without liver injury,,,,,adult,,Non-severe,N,without liver injury,,without liver injury,Alive,29,72.4,Y,62 (46-67),62,46,67,,,,,Y,,15.4 (11-16.8),,,,,,,,,,,,,,,,,,,15.4,11,16.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
37,Xu et al.,26/03/2020,10.1101/2020.03.24.20042408,Acute kidney injury at early stage as a negative prognostic indicator of patients with COVID-19: a hospital-based retrospective analysis,Pre-print,01/01/2020,20/02/2020,,China,Hubei/Anhui,"Patients with confirmed COVID-19 admitted to Union Hospital of Huazhong University of Science and Technology; and COVID-19 patients admitted to the Second People’s Hospital of Fuyang City, in Anhui province.",No,Cohort,Death or discharge,general,,,,,,adult,main,All,N,,,,All,355,54.4,Y,< 50 (45%); 50-69 (41.6%); >=70 (13.2%),59.5,,,,,,,N,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Not clear whether patients remain in hospital at the study end. LOS only mentioned amongst those with AKI who died. Sex/age distribution not specified for this subgroup.
,Xu et al.,,,,,,,,China,,,No,,Death,general,,,,,,adult,,All,N,Acute kidney injury (AKI),,Acute kidney injury (AKI),Dead,56,54.4,N,,59.5,,,,,,,N,10.9 mean,,,,,,,,,,,,,,,,10.9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
38,Yan et al.,30/03/2020,10.1101/2020.03.22.20040832,Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infection,Pre-print,31/01/2020,09/03/2020,,China,Hubei,"Hospitalized, non-critically ill patients with COVID-19 admitted to NO.3 People’s Hospital of Hubei province, that had the available RNA viral data to estimate the duration of viral shedding.",No,,Discharge,general,,,,,,adult,main,All,N,,,,Alive,120,45,Y,52 (35-63) median(IQR),52,35,63,,,,,Y,21 (17-26) median (IQR),,,,,,,,,,,,,21,17,26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Investigating viral shedding so only included patients with RNA viral data. Most patients (99.2%) in the cohort were non-critically ill patients with COVID-19 due to triage strategies. Had 168 pateints admitted over the study period, only reported LOS for 120 that had been discharged."
,Yan et al.,,,,,,,,China,,,No,,,general,,,Lopinavir/Ritonavir,"LPV/ r (400mg and 100mg , orally, twice daily",,adult,,All,N,,Lopinavir/Ritonavir,Lopinavir/Ritonavir,Alive,78,44.9,Y,50 (34-61),50,34,61,,,,,Y,23 (19-27),,,,,,,,,,,,,23,19,27,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Yan et al.,,,,,,,,China,,,No,,,general,,,Control,,,adult,,All,N,,Control,Control,Alive,42,45.2,Y,57 (36.5-66),57,36.5,66,,,,,Y,18.5 (13-22.5),,,,,,,,,,,,,18.5,13,22.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
39,Deng et al.,20/03/2020,10.1097/CM9.0000000000000824,"Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study.",Published,01/01/2020,,21/02/2020,China,"Wuhan, Hubei","Recovered and dead patients admitted two tertiary hospitals in Wuhan (Hankou and Caidian branch of Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, and Hankou branch of Central Hospital of Wuhan)",Yes,Cohort,Discharged,general,,,,,,adult,main,All,N,,,,Alive,116,44,Y,"40 (33, 57) median (Q1,Q3)",40,33,57,,,,,Y,"16 (12, 20) median (Q1,Q3)",,,,"7.0 (5.0, 10.0) median (IQR)",,,,,,,,,16,12,20,,,,,,,,,,,,,,,7,5,10,,,,,,,,,,,,,,,,,,,,,,,,"Only enrolled dead and discharged patients within the study, so data is still censored."
,Deng et al.,,,,,,,,China,,,Yes,,Death,general,,,,,,adult,main,All,N,,,,Dead,109,67,Y,"69 (62, 74) median (Q1,Q3)",69,62,74,,,,,Y,"8 (4, 13) median (Q1,Q3)",,,,"10.0 (6.5, 12.0) median (IQR)",,,,,,,,,8,4,13,,,,,,,,,,,,,,,10,6.5,12,,,,,,,,,,,,,,,,,,,,,,,,
40,Yang et al.,24/02/2020,10.1016/S2213-2600(20)30079-5,"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.",Published,24/12/2019,26/01/2020,09/02/2020,China,"Wuhan, Hubei",Critically ill adult patients with SARS-CoV-2 pneumonia who were admitted to the intensive care unit (ICU) of Wuhan Jin Yin-tan hospital,Yes,"single-centered, retrospective, observational study",Death,ICU,critically ill,those admitted to the intensive care unit (ICU) who required mechanical ventilation or had a fraction of inspired oxygen (FiO2) of at least 60% or more.,,,,adult,main,Severe,N,,,,Dead,32,66,Y,64·6 (11·2) mean (SD),,,,64.6,11.2,,,Y,,,7 (I3–11) median (IQR),,,,11 (7–14) median (IQR),,,,,,,,,,,,,,,,,7,3,11,,,,,,,,,,,,,,,11,7,14,,,,,,,,,,,,,,LOS only presented for those that have died.
,Yang et al.,,,,,,,,China,,,Yes,,Survivors,,,,,,,adult,main,Severe,N,,,,Alive,20,70,Y,51·9 (12·9),,,,51.9,12.9,,,Y,,,,,,,9 (6–12),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9,6,12,,,,,,,,,,,,,,
41,Yuan et al.,29/03/2020,10.1007/s00011-020-01342-0,The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients,Published,11/01/2020,04/02/2020,13/02/2020,China,"Shenzhen, Guangdong",Confirmed COVID-19 patients which were admitted and subsequently discharged from Shenzhen Third People’s Hospital.,Yes,Cohort,Discharged,general,All patients,,,,,adult,main,All,Y,,,,Alive,94,44.7,Y,40 (1–78) median (range),40,,,,,1,78,Y,14.28 (13.61–14.95) mean (95%CI),,,,,,,,,,,,,,,,14.28,3.31,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Study dates in abstract and main text differ (abstract: 5th Jan to Feb 13th; main text: 11th Jan to Feb 4th with follow-up to Feb 13th)
,Yuan et al.,,,,,,,,China,,,Yes,,Discharged,general,Mild,,,,,adult,,Mild,Y,,,,Alive,8,37.5,Y,19 (7–39) median (range),19,,,,,7,39,Y,12.88 (11.36–14.39) mean (95%CI),,,,,,,,,,,,,,,,12.88,2.19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Yuan et al.,,,,,,,,China,,,Yes,,Discharged,general,Moderate,,,,,adult,,Moderate,Y,,,,Alive,75,45.3,Y,40 (1–78) median (range),40,,,,,1,78,Y,14.12 (13.34–14.90) mean (95%CI),,,,,,,,,,,,,,,,14.12,3.45,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Yuan et al.,,,,,,,,China,,,Yes,,Discharged,general,Severe,,,,,adult,,Severe,Y,,,,Alive,11,45.5,Y,63 (32–69) median (range),63,,,,,32,69,Y,16.36 (14.79–17.93) mean (95%CI),,,,,,,,,,,,,,,,16.36,2.66,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
42,Zhang et al.,06/03/2020,10.1101/2020.03.02.20030452,"Clinical features and outcomesof 221 patients with COVID-19 in Wuhan, China",Pre-print,02/01/2020,10/02/2020,15/02/2020,China,"Wuhan, Hubei",Confirmed COVID-19 patients admitted to Zhongnan Hospital of Wuhan University,No,Cohort,Discharge to ward,ICU,,,,,,adult,main,All,N,,,,Alive,23,65.2,Y,62.0(49.0-71.0),62,49,71,,,,,Y,,,8.0(5.0-13.0) median IQR,,,,10.0(7.0-12.0) median IQR,,,,,,,,,,,,,,,,,8,5,13,,,,,,,,,,,,,,,10,7,12,,,,,,,,,,,,,,Patients still hospitalised at the end of the study.
,Zhang et al.,,,,,,,,China,,,No,,Death in ICU,ICU,,,,,,adult,main,All,N,,,,Dead,9,77.8,Y,76.0(57.5-81.5),76,57.5,81.5,,,,,Y,,,11.0(4.5-14.5) median IQR,,,,11.0(8.0-12.0) median IQR,,,,,,,,,,,,,,,,,11,4.5,14.5,,,,,,,,,,,,,,,11,8,12,,,,,,,,,,,,,,
43,Zhang et al.,26/03/2020,10.1101/2020.03.24.20042655,"COVID-19 infection induces readily detectable morphological and inflammation-related phenotypic changes in peripheral blood monocytes, the severity of which correlate with patient outcome",Pre-print,,,,China,Shaanxi,Confirmed COVID-19 patients admitted to Xi’an No.8 Hospital (Shaanxi Provincial Infectious Disease Hospital) and the First Affiliated Hospital of Xi’an Jiaotong University,No,,,,All,,,,,adult,main,All,Y,,,,Alive,28,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Doesn't describe patient characteristics and statistic for non-ICU LOS not specified
,Zhang et al.,,,,,,,,China,,,No,,,general,Non-ICU,,,,,adult,,Non-severe,Y,,,,Alive,25,,,,,,,,,,,,16.24 ± 2.39,,,,,,,,,,,,,,,,16.24,2.39,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
44,Zhao et al.,30/03/2020,10.1101/2020.03.13.20035436,Clinical characteristics and durations of hospitalized patients with COVID-19 in Beijing: a retrospective cohort study,Pre-print,21/01/2020,08/02/2020,29/02/2020,China,,"laboratory-confirmed COVID-19 in Beijing YouAn Hospital, Beijing",No,Cohort,Discharge and death,general,All,,,,,adult,main,All,N,,,,All,77,44.2,Y,52±20,,,,52,20,,,Y,13 (10-18) median (IQR),,,,5 (3-6) median (IQR),,,,,,,,,13,10,18,,,,,,,,,,,,,,,5,3,6,,,,,,,,,,,,,,,,,,,,,,,,Patients still hospitalised at the end of the study.
,Zhao et al.,,,,,,,,China,,,No,,Discharge,general,All,,,,,adult,main,All,Y,,,,Alive,64,44.2,N,,,,,52,20,,,N,13 (10-16.5) median (IQR),,,,5 (4-6) median (IQR),18.5 (15-22)/64,,,,,,,,13,10,16.5,,,,,,,,,,,,,,,5,4,6,18.5,15,22,,,,,,,,,,,,,,,,,,,,,
,Zhao et al.,,,,,,,,China,,,No,,Discharge,general,Non-severe,,,,,adult,,Non-severe,Y,,,,Alive,54,44.2,N,,,,,52,20,,,N,12 (10-16) median (IQR),,,,5 (4-6) median (IQR),18 (15-21),,,,,,,,12,10,16,,,,,,,,,,,,,,,5,4,6,18,15,21,,,,,,,,,,,,,,,,,,,,,
,Zhao et al.,,,,,,,,China,,,No,,Discharge,general,Severe,,,,,adult,,Severe,Y,,,,Alive,10,44.2,N,,,,,52,20,,,N,18.5 (15-21) median (IQR),,,,6 (5-7) median (IQR),24.5 (22-27),,,,,,,,18.5,15,21,,,,,,,,,,,,,,,6,5,7,24.5,22,27,,,,,,,,,,,,,,,,,,,,,
,Zhao et al.,,,,,,,,China,,,No,,Death,general,,,,,,adult,main,All,N,,,,Dead,5,44.2,N,,,,,52,20,,,N,10 (7-17) median (IQR),,,,4 (2-6) median (IQR),,,16 (9-21) median (IQR),,,,,,10,7,17,,,,,,,,,,,,,,,4,2,6,16,9,21,,,,,,,,,,,,,,,,,,,,,
45,Zhou et al.,11/03/2020,10.1016/S0140-6736(20)30566-3,"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",Published,,29/12/2019,31/01/2020,China,"Wuhan, Hubei","All adult (≥18 years) inpatients who were hospitalised for COVID-19 (diagnosed with COVID-19 according to WHO interim guidance) and had a definite outcome (dead or discharged), at Jinyintan Hospital and Wuhan Pulmonary Hospital",Yes,retospective cohort,Death or discharge,general/ICU,,,,,,adult,main,All,N,,,,All,191,62,Y,56·0 (46·0–67·0) median (IQR),56,46,67,,,,,Y,11·0 (7·0–14·0) median (IQR),,8·0 (4·0–12·0) median (IQR),,"11·0 (8·0–14·0), median (IQR)",21·0 (17·0–25·0) median (IQR),12·0 (8·0–15·0) median (IQR),,,,,,,11,7,14,,,,,,,,8,4,12,,,,,11,8,14,21,17,25,,,,,12,8,15,,,,,,,,,,,,,,"The study dates are based on discharge dates and not admission dates. Before Jan 11, 2020, SARS-CoV-2 RNA detection results were not available in the electronic medical records, from which data for this study were obtained retrospectively; therefore, this study includes 29 of the 41 patients originally reported on."
,Zhou et al.,,,,,,,,China,,,Yes,,Death,general/ICU,,,,,,adult,main,All,N,,,,Dead,54,70,Y,69·0 (63·0–76·0),69,63,76,,,,,Y,7·5 (5·0–11·0) median (IQR),,8·0 (4·0–12·0) median (IQR),,"11·0 (8·0–15·0), median (IQR)",18·5 (15·0–22·0),12·0 (8·0–15·0) median (IQR),,,,,,,7.5,5,11,,,,,,,,8,4,12,,,,,11,8,15,18.5,15,22,,,,,12,8,15,,,,,,,,,,,,,,
,Zhou et al.,,,,,,,,China,,,Yes,,Discharge,general/ICU,,,,,,adult,main,All,N,,,,Alive,137,59,Y,52·0 (45·0–58·0),52,45,58,,,,,Y,12·0 (9·0–15·0) median (IQR),,7·0 (2·0–9·0) median (IQR),,"11·0 (8·0–13·0), median (IQR)",22·0 (18·0–25·0) median (IQR),11·5 (8·0–14·0) median (IQR),,,,,,,12,9,15,,,,,,,,7,2,9,,,,,11,8,13,22,18,25,,,,,11,8,14,,,,,,,,,,,,,,
46,Wang et al.,10/04/2020,10.1101/2020.04.07.20057299,"Survival analysis of hospital length of stay of novel coronavirus (COVID-19) pneumonia patients in Sichuan, China",Pre-print,16/01/2020,04/03/2020,04/03/2020,China,Sichuan,"Laboratory-confirmed cases of COVID-19, which were reported to the Sichuan Center for Disease Control and Prevention (CDC) through the National Notifiable Diseases Reporting System (NNDRS).",No,Cross-sectional,Dead or discharged,general,All,,,,,adult,main,All,Y,,,,All,538,53,Y,,,,,,,,,,19 (14-23) median IQR,,,,,,,,,,,,,19,14,23,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Not clear whether patients still-hospitalised were included in the LOS estimate, we have assumed that still-hospitalised patients were included."
,Wang et al.,,,,,,,,China,,,No,,,general,Mild,,,,,adult,,Mild,Y,,,,All,450,53,N,,,,,,,,,,19 (14-23) median IQR,,,,,,,,,,,,,19,14,23,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Wang et al.,,,,,,,,China,,,No,,,general,Severe,,,,,adult,,Severe,Y,,,,All,88,53,N,,,,,,,,,,23 (15-26) median IQR,,,,,,,,,,,,,23,15,26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
47,Wu et al.,09/04/2020,10.1101/2020.03.30.20047365,Neutralizing Antibody Responses to SARS-CoV-2 in a COVID-19 Recovered Patient Cohort and Their Implications,Pre-print,,26/02/2020,26/02/2020,China,Shanghai,adult COVID-19 patients admitted to Shanghai Public Health Clinical Center.,Yes,Cohort,Discharge,general,All,,,,,adult,main,All,N,,,,All,175,47,Y,50 (range 16 to 85 ),50,,,,,16,85,Y,16 (7 -30) meadian range,,,,,,,,,,,,,16,7,30,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Only enrolled discharged and mild patients. No start date for the study provided.
,,,,,,,,,China,,,Yes,,,general,Low,titers of SARS-CoV-2-specific NAbs,,,,adult,,All,N,Titres NAbs - low,,Titres NAbs - low,All,52,36.5,Y,38 (16-68),38,,,,,16,68,Y,14.5 (8-29),,,,,,,,,,,,,14.5,8,29,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,China,,,Yes,,,general,medium-low,,,,,adult,,All,N,Titres NAbs - medium-low,,Titres NAbs - medium-low,All,29,44.8,Y,42 (23-75),42,,,,,23,75,Y,15 (7-28),,,,,,,,,,,,,15,7,28,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,China,,,Yes,,,general,medium high,,,,,adult,,All,N,Titres NAbs - medium-high,,Titres NAbs - medium-high,All,69,52.2,Y,56 (23-77),56,,,,,23,77,Y,16 (8-30),,,,,,,,,,,,,16,8,30,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,China,,,Yes,,,general,high,,,,,adult,,All,N,Titres NAbs - high,,Titres NAbs - high,All,25,56,Y,63 (35-85),63,,,,,35,85,Y,18 (10-29),,,,,,,,,,,,,18,10,29,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
48,Yin et al.,11/04/2020,10.1101/2020.04.07.20053744,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Pregnancy In China: A Retrospective Cohort Study,Pre-print,28/01/2020,28/02/2020,08/03/2020,China,"Wuhan, Hubei","female inpatients (20-40 years old, female) from Jan 28 to Feb 28, 2020, at Wuhan Union and Tongji hospitals of Huazhong University of Science and Technology",No,Cohort,Discharge,general,All,,,,,adult,main,All,N,,,,Alive,66,0,Y,20-40,30,,,,,20,40,Y,17·8±6·1 mean SD,,,,10·7±8·1,,,,,,,,,,,,17.8,6.1,,,,,,,,,,,10.7,8.1,,,,,,,,,,,,,,,,,,,,,,,,,,,"Only include pregnant women. Not clear whether patients still-hospitalised were included in the LOS estimate, we have assumed that still-hospitalised patients were included."
,,,,,,,,,China,,,No,,,general,Pregnant,,,,,adult,,All,N,Pregnant,,Pregnant,Alive,31,0,Y,31·0±4.3,,,,31,4.3,,,Y,17·3±6·9,,,,7·8±7·0,,,,,,,,,,,,17.3,6.9,,,,,,,,,,,7.8,7,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,China,,,No,,,general,Non-pregnant,,,,,adult,,All,N,Non-pregnant,,Non-pregnant,Alive,35,0,Y,32·9±4·8,,,,32.9,4.8,,,Y,18·2±5·6,,,,13·2±8·2,,,,,,,,,,,,18.2,5.6,,,,,,,,,,,13.2,8.2,,,,,,,,,,,,,,,,,,,,,,,,,,,
49,Tian et al.,07/04/2020,10.1101/2020.04.04.20053280,Longitudinal analysis of laboratory findings during the process of recovery for patients with COVID-19,Pre-print,21/01/2020,05/03/2020,,China,Jilin,"three designated tertiary hospitals in Jilin province including the First Hospital of Jilin University (n=3), Changchun Infectious Disease Hospital (n=42), and Siping Infectious Disease Hospital (n=14)",Yes,Cohort,Discharge,general,,,,,,adult,main,All,N,,,,Alive,59,57.6,Y,41 years (IQR: 29-52),41,29,52,,,,,Y,17 (11-20) median IQR,,,,,,,,,,,,,17,11,20,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Dates are different in abstract and main text.
50,Petrilli et al.,11/04/2020,10.1101/2020.04.08.20057794,"Factors associated with hospitalization and critical illness among 4,103 patients with Covid-19 disease in New York City",Pre-print,01/03/2020,02/04/2020,07/04/2020,USA,New York,all patients with laboratory-confirmed Covid-19 treated at an academic health system in New York City (NYU Langone Health),No,Cross-sectional,Discharge or death,general,All,,,,,adult,main,All,Y,,,,All,1273,50.5,Y,"52 years (interquartile range, 36 to 65)",52,36,65,,,,,Y,"4.8 days (interquartile range, 3.3 to 7.6",,,,,,,,,,,,,4.8,3.3,7.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"In the critical illness, some patients still hospitalised at the end of the study. In the non-critical all patients discharged (no deaths)"
,,,,,,,,,USA,,,No,,Discharge,general,Non-critical,,,,,adult,,Non-severe,Y,,,,Alive,932,60.1,Y,58 (46-71),58,46,71,,,,,Y,4 (2-6) median IQR,,,,,,,,,,,,,4,2,6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,USA,,,No,,Discharge or death,general,Critical,,,,,adult,,Severe,Y,,,,All,341,68,Y,67 (56-77),67,56,77,,,,,Y,6 (3-9),,,,,,,,,,,,,6,3,9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
51,Zeng et al.,11/04/2020,10.1101/2020.04.06.20054825,"Hypertension in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study",Pre-print,05/01/2020,08/03/2020,08/03/2020,China,"Wuhan, Hubei","Hankou Hospital, patients >= 18 years, entire stay in hospital >=48 hours. Confirmed cases of COVID-19",No,Cohort,Discharge or death,general,All,,,,,adult,main,All,N,,,,All,274,55,Y,60 (15) mean (SD),,,,60,15,,,Y,20 (14-27) median (IQR),,,,,,,,,,,,,20,14,27,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Excluding short hospital stays (<less 48 hours). Not clear whether LOS estimate includes still-hospitalised patients, or only those who are discharges/dead."
,,,,,,,,,China,,,No,,Discharge or death,general,Hypertension,,,,,adult,,All,N,Hypertension,,Hypertension,All,75,55,Y,67 (11) mean (SD),,,,67,11,,,Y,22 (15-26) median (IQR),,,,,,,,,,,,,22,15,26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,China,,,No,,Discharge or death,general,Hypertension - ACEI/ARB previous treatment,,,,,adult,,All,N,Hypertension - ACEI/ARB previous treatment,,Hypertension - ACEI/ARB previous treatment,All,28,43,Y,64 (12) mean (SD),,,,64,12,,,Y,21 (15-25) median (IQR),,,,,,,,,,,,,21,15,25,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,China,,,No,,Discharge or death,general,Hypertension - no ACEI/ARB previous treatment,,,,,adult,,All,N,Hypertension - no ACEI/ARB previous treatment,,Hypertension - no ACEI/ARB previous treatment,All,47,49,Y,69 (10) mean (SD),,,,69,10,,,Y,22 (16-28) median (IQR),,,,,,,,,,,,,22,16,28,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,China,,,No,,Discharge or death,general,Non-Hypertension,,,,,adult,,All,N,Non-Hypertension,,Non-Hypertension,All,199,55,Y,58 (15) mean (SD),,,,58,15,,,Y,19 (13-28) median (IQR),,,,,,,,,,,,,19,13,28,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
52,Xiao et al.,08/04/2020,10.1101/2020.04.06.20055194,"Acute kidney injury in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study",Pre-print,05/01/2020,08/03/2020,08/03/2020,China,Hubei,"""Hankou Hospital, COVID-19 confirmed patients >=18 years, entire stay in hospital >=48 hours, not
 undergone renal replacement therapy (RRT) before admission""",No,Cohort,Discharge or death,general,All,,,,,adult,main,All,N,,,,All,287,55.7,Y,62 (51-70) median (IQR),62,51,70,,,,,Y,18 (12 -23) median (IQR),,,,,,,,,,,,,18,12,23,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"Not clear whether LOS estimate includes still-hospitalised patients, or only those who are discharges/dead."
,,,,,,,,,China,,,No,,Discharge or death,general,Non-Acute Kidney Injury (AKI),,,,,adult,,All,N,Non-Acute Kidney Injury (AKI),,Non-Acute Kidney Injury (AKI),All,232,52.6,Y,60 (49-69) median (IQR),60,49,69,,,,,Y,18 (13 -23) median (IQR),,,,,,,,,,,,,18,13,23,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,China,,,No,,Discharge or death,general,AKI - stage 1,"Stage 1: Increase in serum creatinine to 1.5 to 1.9 times baseline, or increase
 in serum creatinine by ≥26.5 μmol/L.",,,,adult,,All,N,AKI - stage 1,,AKI - stage 1,All,41,69.1,N,67 (57-74) median (IQR),67,57,74,,,,,N,22.5 (8.3 - 28) median (IQR),,,,,,,,,,,,,22.5,8.3,28,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,China,,,No,,Discharge or death,general,AKI - stage 2&3,"Stage 2: Increase in serum creatinine to 2.0 to 2.9 times baseline.
 Stage 3: Increase in serum creatinine to 3.0 times baseline, or increase in serum creatinine to ≥353.6
 μmol/L, or the initiation of renal replacement therapy.",,,,adult,,All,N,AKI - stage 2&3,,AKI - stage 2&3,All,14,69.1,N,68 (57-74) median (IQR),68,57,74,,,,,N,12 (4.5 - 17.8),,,,,,,,,,,,,12,4.5,17.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
